Sense Neuro Diagnostics has been awarded a $2 million contract by the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) through the Traumatic Brain Injury and Psychological Health Research Program (TBI PHRP).
This funding will support clinical trials for Sense’s NeuroHawk device, which is designed to detect hemorrhage in specific regions of the brain and provide rapid diagnosis of TBI on the front lines of care.
The clinical trial, set to begin in June 2025, will evaluate the capabilities of the NeuroHawk device to diagnose TBI and localiSe brain hAemorrhage, offering critical insights in high-pressure environments.
With a period of performance of 30 months, this contract marks the second direct military funding the company has received, with the first coming through the Medical Technology Enterprise Consortium (MTEC) to build the NeuroHawk technology and derive initial algorithms for hemorrhage detection.
Geoff Klass IS CEO of Sense Neuro Diagnostics.
He said: “We are honoured to receive this contract from CDMRP as it recognises the potential of our technology to address a significant unmet need for both military personnel and civilian patients.
“The NeuroHawk is designed for use in field conditions, allowing for rapid detection and monitoring of brain injuries.
“With this support, we are poised to advance the development and deployment of life-saving technology.”
Traumatic Brain Injury (TBI) has become a hallmark injury in modern warfare, affecting over 420,000 service members in the past two decades.
As warfare continues to evolve, with emerging challenges like drone and trench combat in conflicts such as the ongoing war in Ukraine, the need for effective, point-of-injury diagnosis tools is more urgent than ever.
Traditional methods of TBI diagnosis are limited and often rely on subjective measures, which may delay critical care.
The NeuroHawk device is a non-invasive brain scanner that utilises advanced, low-power radio frequency (RF) technology to detect and monitor TBI and brain haemorrhage in seconds.
This rapid, objective diagnosis capability could significantly improve triage and treatment decisions on the battlefield, reducing the risk of secondary injury and improving outcomes for those with the most acute needs.
The NeuroHawk device is also being tested for use in hospital and EMS markets, where it could provide rapid diagnosis and continuous monitoring for stroke and brain injury patients.
Sense Neuro Diagnostics plans to file for FDA clearance Q1 2025 and begin a full commercial launch mid 2025.
Klass said: “The support we’ve received from the military is a testament to the strength of our technology and the impact it can have beyond the battlefield.
“This funding allows us to continue developing a technology that can change the standard of care for brain injury patients globally.”
